✦Canada Post Xpress1–2 day delivery across CanadaFree on orders over $200
Your cart is empty
Dual GHRH / GHS-R Research Blend
CJC-1295 + Ipamorelin is commonly studied for its combined role in modulating growth hormone signaling pathways and supporting pulsatile GH release in research models. It’s often explored for its effects on recovery dynamics, tissue maintenance, and overall metabolic regulation within controlled laboratory settings.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
CJC-1295 + Ipamorelin is a dual-peptide research formulation combining a growth hormone–releasing hormone (GHRH) analogue with a selective ghrelin receptor (GHS-R1a) agonist. It is developed for controlled laboratory investigation involving hypothalamic-pituitary signaling systems.
In scientific literature, CJC-1295 is studied in models examining GHRH receptor activation pathways, while ipamorelin is evaluated for its interaction with ghrelin receptor signaling frameworks. Together, the blend is researched in experimental systems exploring coordinated receptor-mediated endocrine signaling under in vitro and preclinical conditions.
Third-party tested for purity, identity, quantity.
This blend integrates two peptides studied within endocrine signaling research frameworks. CJC-1295 is evaluated in GHRH receptor activation models, while ipamorelin is examined in ghrelin receptor interaction systems. Experimental studies assess their combined behavior within hypothalamic-pituitary axis signaling environments under controlled laboratory conditions.
Research publications have explored receptor interaction dynamics and pathway-level regulatory mechanisms associated with GHRH and GHS-R signaling systems.
CJC-1295 was developed during investigations into stabilized GHRH analogues, while ipamorelin emerged from research into selective growth hormone secretagogues targeting the ghrelin receptor.
The combined formulation reflects laboratory interest in coordinated receptor pathway research involving both GHRH and GHS-R signaling mechanisms.
Laboratory investigations involving CJC-1295 and ipamorelin have focused on GHRH and ghrelin receptor activation models, hypothalamic-pituitary axis signaling, and endocrine regulatory pathway interaction systems. Research frameworks evaluate coordinated receptor-mediated signaling dynamics under controlled in vitro and preclinical conditions.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 5mg of CJC-1295 and 5mg of ipamorelin, totaling 10mg of lyophilized peptide blend. Independent third-party testing verifies purity, identity, and batch composition.
The vial contains only the lyophilized peptide blend. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 91(3):799–805.
PubMedIpamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 139(5):552–561.
PubMedA receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273(5277):974–977.
PubMedRelated
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$180.00
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$10.00
Immune-modulating peptide studied for T-cell signaling and immune system regulatory pathway research
From$70.00
GHRH analog studied for growth hormone regulation and metabolic pathway signaling research
From$95.00
